Q2
CRVO — Q2 2026 Financial Report Analysis
CervoMed ended Q2 2026 with $24.9M in cash after June raises lifted its going-concern warning and extended runway to Q3 2027, but shares outstanding rose 63% and the net loss widened to $6.6M as grant revenue ended.